Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records

Kakara, Makoto; Nomura, Hiroko; Ezaki, Mai; Fukae, Masato; Hirota, Tomoyoshi; Matsubayashi, Sunao; Hirakawa, Masakazu; Ieiri, Ichiro

doi:10.1016/j.jdiacomp.2016.06.009

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most published studies analyzed the effects of 3-12 months of treatment. All the currently used OADs treatments have shown their effectiveness in decreasing the HbA1c level, with a mean decrease of 1-2 % for biguanides [9,10], 0.5-2 % for SUs [11][12][13], 0.5-2.8 % for GLP1-RAs [10,[14][15][16], 0.6-1.2 % for DPP4-Is [17][18][19][20][21][22][23][24][25][26][27][28][29][30], 0.5-1.3 % for AGIs [31][32][33], 0.8 % for glinides [34], 0.7 % for SGLT-2 inhibitors [35][36][37]. Insulin treatment is more effective and is associated with a mean decrease the HbA1c level of 1.5-2 % [38,39].…”

Section: Introductionmentioning

confidence: 99%

Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin

Boullenger¹,

Quindroit²,

Legrand³

et al. 2022

Primary Care Diabetes

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin

Boullenger¹,

Quindroit²,

Legrand³

et al. 2022

Primary Care Diabetes

View full text Add to dashboard Cite

“…Because the concentrations of most medicines are not routinely measured in hospitals, a PPD analysis without pharmacokinetic (PK) data represents a practical method to assess this information. Our research group previously conduced PPD analyses based on electronic medical records; however, these studies were conducted at a single hospital. Therefore, our PPD models may be limited in terms of robustness and reliability.…”

mentioning

confidence: 99%

Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals

Muraki

Moriki

Shigematsu

et al. 2017

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)-lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospitals). Interhospital differences in the PPD model were also evaluated. We conducted the following 2 approaches to build the PPD models. A PPD model was developed separately using individual hospital data, and structural models and covariates between the two hospitals were compared (approach A). Another PPD model was developed using all available data from both hospitals, and differences between the 2 hospitals were evaluated by performing a covariate analysis on all PPD parameters (approach B). PPD analyses were performed by NONMEM using data from 358 patients. In both approaches, one indirect response model was established. In approach A, 2 diuretics (loops and thiazides) and renal function tests (Scr or BUN) were selected as covariates for the UA baseline level (serum UA levels just before the febuxostat treatment), whereas 2 diuretics and BUN were selected in approach B. A covariate analysis indicated that loops and thiazides increased UA baseline levels by 7%-14% and 6%-11%, respectively. In approach B, "hospital" was identified as a significant covariate for the UA baseline level; the baseline level was 7% higher in the city hospital. A PPD analysis may provide a precise description of the time course of the UA-lowering effects of febuxostat and quantitatively detect an interhospital difference in the UA baseline level.

show abstract

Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records

Cited by 2 publications

References 31 publications

Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin

Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin

Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals

Contact Info

Product

Resources

About